Form 6-K ASTRAZENECA PLC For: Jun 09
Tweet
Share
E-mail
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of June 2023
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes
__
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
9 June 2023
Nirsevimab unanimously recommended by FDA Advisory Committee for
the
prevention of RSV lower respiratory tract disease in
infants
If approved, nirsevimab would be the first preventive option
specifically designed to
protect the broad infant population through its first RSV
season
Across all clinical endpoints, a single dose of nirsevimab
delivered consistent and
sustained efficacy against RSV disease vs placebo
The US Food and Drug Administration (FDA) Antimicrobial Drugs
Advisory Committee (AMDAC) has voted unanimously 21 to 0 that
AstraZeneca and Sanofi's nirsevimab has a favourable benefit risk
profile for the prevention of respiratory syncytial virus (RSV)
lower respiratory tract disease (LRTD) in newborns and infants born
during or entering their first RSV season. The Committee also voted
19 to 2 in support of nirsevimab's favourable benefit risk profile
for children up to 24 months of age who remain vulnerable to severe
RSV disease through their second RSV season.
Nirsevimab has the potential to protect the broad infant population
through its first RSV season, including those born healthy at term
or preterm, or with specific health conditions that make them
vulnerable to RSV disease. The single dose can be flexibly
administered at the beginning of the RSV season or at birth for
newborns born during the RSV season.
The FDA accepted the Biologics License Application (BLA) for
nirsevimab in 2022 and the agency has indicated it will work to
expedite its review. The Prescription Drug User Fee Act date is in
the third quarter of 2023. If approved by that time, nirsevimab
will be available in the US ahead of the 2023-2024 RSV
season.
Dr William Muller, Associate Professor, Pediatrics, Northwestern
University Feinberg School of Medicine and Scientific Director,
Clinical and Community Trials, Ann & Robert H. Lurie Children's
Hospital of Chicago, Illinois, US said: "RSV remains the most
common cause of bronchiolitis and pneumonia in infants, and the
inability to predict which infants will develop severe RSV disease
leads to uncertainty for new parents and for physicians. The
innovation of nirsevimab as a long-acting antibody that can be
conveniently administered to a broad infant population with a
single-dose at the time protection is most needed is a
significant public health advancement that could have far-reaching
impact on the well-being of our families and healthcare systems in
the US."
Iskra Reic, Executive Vice President, Vaccines and Immune
Therapies, AstraZeneca, said: "We are delighted that the
Antimicrobial Drugs Advisory Committee has unanimously recognised
the favourable benefit risk profile of nirsevimab as the first
preventative option against RSV for a broad infant population.
Nirsevimab builds on AstraZeneca's strong science, leadership in
RSV and commitment to addressing the needs of the most vulnerable.
We look forward to continuing to work with the FDA to complete
their expedited review, and we hope to see nirsevimab available as
soon as possible given the significant burden of RSV in
infants."
Thomas Triomphe, Executive Vice President, Vaccines, Sanofi, said:
"Most babies hospitalised with RSV are born at term and healthy,
which is why interventions specifically designed to protect all
infants are likely to result in the greatest impact. We are
encouraged by the Advisory Committee's positive vote based on the
compelling clinical development program supporting nirsevimab and
its breakthrough potential to reduce the magnitude of annual RSV
burden."
RSV is a very contagious virus that can lead to serious respiratory
illness, according to the Centers for Disease Control and
Prevention (CDC).1 In
the US, RSV is the leading cause of hospitalisation for babies
under one.2 About
75% of infants hospitalised for RSV in the US were born at term
with no underlying conditions.3
The AMDAC based its recommendation on the nirsevimab clinical
development programme spanning three pivotal late-stage clinical
trials, including results from the MELODY Phase III trial recently
published in the New
England Journal of Medicine.4-8 Across
all clinical endpoints, a single dose of nirsevimab demonstrated
sustained and consistent reduction in RSV LRTD requiring medical
care vs placebo through the entire RSV season. Nirsevimab was
generally well tolerated with a favourable safety profile that was
consistent across all clinical trials. The overall rates of adverse
events were comparable between nirsevimab and placebo and the
majority of adverse events were mild or moderate in severity. The
most common adverse events were rash, fever and injection site
reactions.4-10
Notes
Antimicrobial Drugs Advisory Committee (AMDAC)
AMDAC reviews and evaluates available data concerning the safety
and effectiveness of marketed and investigational human drug
products for use in the treatment of infectious diseases and
disorders and makes appropriate recommendations to the Commissioner
of Food and Drugs. The AMDAC's recommendation, while not binding,
will be considered by the FDA during its review of the BLA for
nirsevimab.
RSV
RSV is a very contagious virus that can lead to serious respiratory
illness for infants, according to the CDC.1 Two
out of three infants are infected with RSV during their first year
of life and almost all infants are infected by their second
birthday.11 In
the US, RSV is the leading cause of hospitalisation in infants
under 12 months.2 Approximately
75% of infants hospitalised for RSV were born healthy and at term
with no underlying conditions in a study conducted from
2014-2015.3 RSV
symptoms can include runny nose, coughing, sneezing, fever,
decrease in appetite, and wheezing.1 Each
year RSV infection leads to approximately 500,000 emergency
department visits in the US by children under 5 years of age, which
represents 1 in 4 of all RSV-related doctor visits, according to
the CDC.12
Nirsevimab
Nirsevimab is a single dose long-acting antibody, developed and
commercialised in partnership by AstraZeneca and Sanofi using
AstraZeneca's YTE technology. It is designed to protect infants
born during or entering their first RSV season and for children up
to 24 months of age who remain vulnerable to severe RSV disease
through their second RSV season. Nirsevimab, provided directly to
newborns and infants as a single dose, offers RSV protection via an
antibody to help prevent LRTD caused by RSV. Monoclonal antibodies
do not require the activation of the immune system to help offer
timely, rapid and direct protection against
disease.13
Nirsevimab has been granted regulatory and other designations to
facilitate expedited development by several major regulatory
agencies around the world. These include Breakthrough Therapy
Designation and Priority Review designation by the China Center for
Drug Evaluation under the National Medical Products
Administration; Breakthrough Therapy
Designation from the US
Food and Drug Administration; access granted to the European
Medicines Agency (EMA) PRIority
Medicines (PRIME) scheme;
and named "a medicine for prioritized development" under the
Project for Drug Selection to Promote New Drug Development in
Pediatrics by the Japan Agency for Medical Research and Development
(AMED). Nirsevimab was approved in the European Union in October
2022.
Pivotal clinical trials
The Phase IIb study (Trial 03) was a randomised, placebo-controlled
trial designed to measure the efficacy of nirsevimab against
medically attended Lower Respiratory Tract Infection (LRTI) through
150 days postdose. Healthy preterm infants of 29-35 weeks'
gestation were randomised (2:1) to receive a single 50mg
intramuscular injection of nirsevimab or
placebo.6
The dosing regimen was recommended based on further exploration of
the Phase IIb data.6 The
subsequent Phase III study, MELODY (Trial 04) applied the
recommended dosing regimen.4,5
The MELODY Phase III study was a randomised, placebo-controlled
trial conducted across 21 countries designed to determine efficacy
of nirsevimab against medically attended LRTI due to RSV confirmed
by reverse transcriptase polymerase chain reaction testing through
150 days after dosing, versus placebo, in healthy late preterm and
term infants (35 weeks gestational age or greater) entering their
first RSV season.4,5
MEDLEY (Trial 05) was a Phase II/III, randomised,
double-blind, Synagis-controlled trial with the primary objective of
assessing safety and tolerability for nirsevimab in preterm infants
and infants with congenital heart disease (CHD) and/or chronic lung
disease of prematurity (CLD) eligible to
receive Synagis.7 Between
July 2019 and May 2021 approximately 918 infants entering their
first RSV season were randomised to receive a single 50mg (in
infants weighing <5kg) or 100mg (in infants weighing ≥5kg)
intramuscular injection of nirsevimab or Synagis. Safety was assessed by monitoring the occurrence
of TEAEs and TESAEs through 360 days post-dose.7 Serum
levels of nirsevimab following dosing (on day 151) in this trial
were comparable with those observed in the MELODY Phase III trial,
indicating similar protection in this population to that in the
healthy term and late preterm infants is likely.7 Data
was published in the New
England Journal of Medicine (NEJM) in March 2022.
The safety profile of nirsevimab was similar
to Synagis in the MEDLEY Phase II/III and consistent
with the safety profile in term and preterm infants studied in the
MELODY Phase III trial.4,5,7 While
uncommon, the most reported adverse reactions were: rash 14 days
post-dose, (the majority of which were mild to moderate); pyrexia
(fever) within 7 days post-dose; non-serious injection site
reactions within 7 days post-dose.
The results of MELODY, MEDLEY Phase II/III and the Phase IIb trials
demonstrate that a single dose of nirsevimab helps protect infants
during their first RSV season against RSV
disease.4-8 This
broad infant population includes preterm, healthy late preterm and
term infants, as well as infants with specific
conditions.
These trials formed the basis of regulatory submissions which began
in 2022.
Results from the MELODY Phase III trial (Trial 04)
The primary endpoint of the MELODY Phase III trial was met,
reducing the incidence of medically attended LRTI, such as
bronchiolitis or pneumonia, caused by RSV by 74.5% (95% CI 49.6,
87.1; P<0.001) compared to placebo. Infants were randomised
(2:1) to receive a single 50mg (in infants weighing <5kg) or
100mg (in infants weighing ≥5kg) intramuscular injection of
nirsevimab or placebo. Between July 2019 and March 2020, 1,490
infants were randomised to receive either nirsevimab or placebo at
the RSV season start.4,5 Data
was published in NEJM in
March 2022.
Following the analysis of the initial 1,490 infants within the
MELODY primary cohort, additional infants continued to be enrolled.
A total of 3,012 healthy late preterm and term infants (35 weeks
gestational age or greater) entering their first RSV season were
randomised to receive nirsevimab (n=2,009) or placebo (n=1,003). In
this updated analysis of the full enrolment cohort, nirsevimab
demonstrated a 76.8% (95% CI: 49.4, 89.4) reduction in
hospitalisation-associated RSV LRTI vs placebo. Additionally,
nirsevimab reduced very severe MA RSV LRTI by 78.6% (95% CI: 48.8,
91.0) through an RSV season, and efficacy against MA RSV LRTI was
consistent with previous trials (76.4%; 95% CI: 62.3, 85.2). The
safety profile of nirsevimab was similar to placebo (nirsevimab,
1.3%; placebo, 1.5%).4
Medically Attended LRTI and Hospitalisation for RSV LRTI Through
150 Days Postdose (ITT population)
|
Endpoints and analyses, n (%)
|
Nirsevimab(N = 994)
|
Placebo(N = 496)
|
Efficacy
(95% CI)
|
P value
|
|
Medically attended RSV LRTI
|
|
|
74.5 (49.6, 87.1)
|
<0.001
|
|
Observed events
Participants requiring imputation of data*
|
12 (1.2)
15 (1.5)
|
25 (5.0)
6 (1.2)
|
|
|
|
Hospitalisation for RSV LRTI
Observed events
Participants requiring imputation of data*
|
6 (0.6)
15 (1.5)
|
8 (1.6)
6 (1.2)
|
62.1 (-8.6, 86.8)
|
0.07
|
*Data were imputed for
participants who had no events and were not followed through 150
days postdose. Analyses were conducted using Poisson regression
with robust variance. CI, confidence interval; ITT,
intent-to-treat; LRTI, lower respiratory tract infection; RRR,
relative risk reduction; RSV, respiratory syncytial
virus.
Results from the Phase IIb trial (Trial 03)
The primary endpoint of the Phase IIb study was met, reducing the
incidence of medically attended LRTI, caused by RSV by 70.1% (95%
CI: 52.3, 81.2) compared to placebo. Between November 2016 and
December 2017, 1,453 infants were randomised (nirsevimab, n=969;
placebo, n=484) at the RSV season start. Research was conducted by
AstraZeneca in both hemispheres, at 164 sites in 23
countries.6 Data
was published in NEJM in
July 2020.
Medically Attended LRTI and Hospitalisation for RSV LRTI Through
150 Days Postdose (ITT population)
|
Endpoints and analyses, n (%)
|
Nirsevimab(N = 969)
|
Placebo(N = 484)
|
Efficacy
(95% CI)
|
P value
|
|
Medically attended RSV LRTI
|
|
|
70.1 (52.3, 81.2)
|
<0.001
|
|
Observed events
Participants requiring imputation of data*
|
25 (2.6)
24 (2.5)
|
46 (9.5)
11 (2.3)
|
|
|
|
Hospitalisation for RSV LRTI
Observed events
Participants requiring imputation of data*
|
8 (0.8)
24 (2.5)
|
20 (4.1)
11 (2.3)
|
78.4 (51.9, 90.3)
|
<0.001
|
*Data were imputed for
participants who had no events and were not followed through 150
days postdose. Analyses were conducted using Poisson regression
with robust variance. CI, confidence interval; ITT,
intent-to-treat; LRTI, lower respiratory tract infection; RRR,
relative risk reduction; RSV, respiratory syncytial
virus.
Sanofi Alliance
In March 2017, AstraZeneca and Sanofi announced an
agreement to develop and commercialise nirsevimab. Under the terms
of the agreement, AstraZeneca leads development and manufacturing
activities, and Sanofi leads commercialisation activities and
records revenue. The two companies share costs and profits in all
territories except in the US. AstraZeneca's revenue from the
agreement is reported as Alliance Revenue and Collaboration Revenue
in the Company's financial statements. Following
a revision to
the profit-sharing arrangement relating to the development and
commercialisation of nirsevimab in the US between AstraZeneca,
Sanofi and Sobi, Sobi has entered into a direct relationship with
Sanofi, replacing the previous participation agreement with
AstraZeneca entered into in November 2018.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1.
Centers for Disease Control and Prevention. RSV in Infants and
Young Children. October 28, 2022.
https://www.cdc.gov/rsv/high-risk/infants-young-children.html.
Accessed June 2023.
2.
Leader S, Kohlhase K. Recent trends in severe respiratory syncytial
virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5
Suppl):S127-S132. doi:10.1067/s0022-3476(03)00510-9.
3. Esposito S, et al. RSV Prevention
in All Infants: Which Is the Most Preferable Strategy? Front
Immunol. 2022; 13: 880368. doi:
10.3389/fimmu.2022.880368.
4.
Muller WJ, et al. Nirsevimab for Prevention of RSV in Term and
Late-Preterm Infants. N Engl J Med. April 5, 2023. doi:
10.1056/NEJMc2214773
5.
Hammitt LL, et al. Nirsevimab for Prevention of RSV in Healthy
Late-Preterm and Term Infants. N Engl J Med. 2022;386 (9): 837-846.
Doi: 10.1056/NEJMoa2110275.
6.
Griffin P, et al. Single-Dose Nirsevimab for Prevention of RSV in
Preterm Infants. N Engl J Med. 2020;383: 415-425. doi:
10.1056/NEJMoa1913556.
7. Domachowske J, MD et
al. Safety of Nirsevimab for RSV in
Infants with Heart or Lung Disease or Prematurity. N Engl J Med.
2022; 386 (9).
8.
AstraZeneca. Beyfortus (Nirsevimab) for the
Prevention of RSV Lower Respiratory Tract Disease in Infants and
Children. Briefing Document for US FDA Antimicrobial Drugs Advisory
Committee Meeting. June 6, 2023. https://www.fda.gov/media/169226/download. Accessed
June 2023.
9.
Simões EAF, et al. Efficacy of nirsevimab against respiratory
syncytial virus lower respiratory tract infections in preterm and
term infants, and pharmacokinetic extrapolation to infants with
congenital heart disease and chronic lung disease: a pooled
analysis of randomised controlled trials. Lancet Child Adolesc
Health 2023. doi: 10.1016/S2352-4642(22)00321.
10.
Wilkins D, et al. Nirsevimab for the prevention of respiratory
syncytial virus infection: neutralizing antibody levels following a
single dose. ESPID 2022 Congress; 2022 May 9-13. Hybrid
Congress.
11. Walsh, EE. Respiratory
Syncytial Virus infection: an illness for all ages. Clin Chest Med.
2017; 38(1):29-36.
12.
Hall, C. B. et al. The burden of respiratory syncytial virus
infection in young children. New Engl J Medicine 360, 588-98
(2009).
13. Centers for Disease
Control and Prevention. Vaccines & Immunizations. September 24,
2021. https://www.cdc.gov/vaccines/vac-gen/immunity-types.htm.
Accessed June 2023.
Adrian Kemp
Company Secretary
AstraZeneca PLC
AstraZeneca PLC
INDEX
TO EXHIBITS
AstraZeneca agreement with Quell Therapeutics
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
09 June 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Q1 2024 results
- Arco Vara unaudited consolidated interim report for Q1 of 2024
- Prospera Energy Inc. 2024 Corporate Update
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
